Loading...

Vertex Pharmaceuticals Incorporated

VRTXNASDAQ
Healthcare
Biotechnology
$388.94
$-6.18(-1.56%)

Vertex Pharmaceuticals Incorporated (VRTX) Stock Overview

Explore Vertex Pharmaceuticals Incorporated’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 72.4/100

Key Financials

Market Cap99.7B
P/E Ratio27.41
EPS (TTM)$14.07
ROE0.22%
Fundamental Analysis

AI Price Forecasts

1 Week$451.16
1 Month$447.55
3 Months$524.42
1 Year Target$531.05

VRTX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Vertex Pharmaceuticals Incorporated (VRTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 37.99, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $531.05.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 27.41 and a market capitalization of 99.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;